Abstract
BackgroundThe -2518A/G (rs1024611) polymorphism of the CCL2 (C-C motif chemokine ligand 2), also known as MCP-1 (monocyte chemotactic protein-1) gene, has been reported to be associated with increased gynecological cancer risk, but the results are conflicting.MethodsIn this analysis, 1089 cases and 1553 controls from six publications were used to investigate the association between CCL2-2518A/G (rs1024611) polymorphism and the risk of gynecological cancer with a meta-analytic approach. Studies published on EBSCO, EMBASE, Web of Science, PubMed, SpringerLink, ScienceDirect, Weipu, and CNKI databases were identified (last update was on November 3, 2015). Six articles focused on the association between CCL2-2518A/G (rs1024611) polymorphism, and gynecological cancer risk was selected and data were extracted. The cancer type included endometrial cancer (n = 1), breast cancer (n = 2), ovarian cancer (n = 2), and cervical cancer (n = 1). All statistical analyses were performed using the STATA version 12.0 software.ResultsThe meta-analysis showed that CCL2-2518A/G (rs1024611) polymorphism is associated with risk of gynecological cancer (GG vs AG + AA, OR = 1.55, 95%CI = 1.07–2.24, P < 0.05; AA vs GG, OR = 0.59 95%CI = 0.38–0.92, P < 0.05). Notably, the subgroup analysis demonstrated that the genotype AA is associated with a reduced gynecological cancer risk in Asians, but an increased risk when compared to AG in Europeans.ConclusionsOur data demonstrated the CCL2-2518A/G (rs1024611) polymorphism is significantly associated with risk of gynecological cancer, and the association differs by ethnicity.
Highlights
The -2518A/G polymorphism of the Chemokine ligand 2 (CCL2) (C-C motif chemokine ligand 2), known as Monocyte chemoattractant protein-1 (MCP-1) gene, has been reported to be associated with increased gynecological cancer risk, but the results are conflicting
Study identification and selection A systematic literature search was initiated in the EBSCO, EMBASE, Web of science, PubMed, SpringerLink, ScienceDirect, Weipu, and Chinese National Knowledge Infrastructure (CNKI) databases to identify articles that evaluated the association between polymorphism of the CCL2 gene and gynecological cancer risk
Inclusion criteria of the eligible studies were as follows: case-control studies, cases were patients with gynecologic cancer, controls consisted of healthy individuals, articles were used to evaluate the association between CCL2-2518A/G polymorphism and gynecologic cancer risk, and Odds ratios (ORs) and 95% CI of the genotype or allele were reported in the studies
Summary
The -2518A/G (rs1024611) polymorphism of the CCL2 (C-C motif chemokine ligand 2), known as MCP-1 (monocyte chemotactic protein-1) gene, has been reported to be associated with increased gynecological cancer risk, but the results are conflicting. Gynecological cancer, including breast cancer (BC), endometrial carcinoma (EC), cervical cancer (CC), and ovarian cancer (OC), is the leading cause of cancerrelated death in women. According to GLOBOCAN 2012 statistics, there were approximately 266,000 women who died of cervical cancer worldwide [2]. Chemokines are proteins with low molecular weight (approximately 8–12 KD) that can induce leukocytes, including monocytes, neutrophil granulocytes, lymphocytes, tumor-associated macrophages (TAMs), natural killer (NK), and dendritic cells, into the area with infection. Chemokines and their receptors are associated with inflammation, cancer, allergy, autoimmunity, and AIDS [3]. Several studies showed that they play a critical role in pathological and physiological functions of the human body [4]
Sign-in/Register to view highlights & summary 
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
